Table 1.

Systemic Immunoglobulin G to Capsular Polysaccharide for the Vaccine Serotypes

Serotype	PCV13 Fold-Change 4 wk/BL	Adjusted P Value	PCV13 Fold-Change 7 wk/BL	Adjusted P Value	HepA Fold-Change 4 wk/BL	Adjusted P Value	HepA Fold-Change 7 wk/BL	Adjusted P Value
1	3.28 (1.76–5.91)	.001	1.63 (1.24–4.16)	.330	0.99 (0.83–1.07)	>.99	0.93 (0.89–0.98)	.38
3	1.25 (1.06–1.51)	.129	1.25 (0.85–1.54)	>.99	0.93 (0.84–1.07)	>.99	0.90 (0.83–1.09)	>.99
4	4.18 (3.05–5.64)	<.0001	2.57 (2.41–3.84)	.023	0.87 (0.80–0.95)	.58	0.82 (0.75–1.0)	.08
5	4.74 (3.46–13.83)	<.0001	4.71 (2.90–16.08)	.012	1.13 (0.93–1.33)	>.99	1.16 (1.01–1.35)	.14
6B	4.94 (3.11–17.51)	.009	6.45 (3.30–12.91)	.017	0.81 (0.76–0.97)	.72	1.62 (1.0–4.18)	.72
7F	2.97 (2.27–14.29)	<.0001	2.92 (1.88–10.70)	.012	0.91 (0.87–1.03)	>.99	1.07 (0.80–1.20)	>.99
9V	7.60 (5.32–8.53)	<.0001	5.55 (3.91–7.35)	.023	0.86 (0.65–1.08)	.87	0.97 (0.61–1.0)	.23
14	9.96 (8.58–13.85)	<.0001	7.53 (6.16–11.59)	.023	0.92 (0.77–0.95)	.38	0.86 (0.71–0.93)	.020
18C	11.46 (3.73–16.17)	.001	8.15 (3.55–11.21)	.076	0.84 (0.81–0.93)	.38	0.86 (0.81–0.98)	.14
19A	4.44 (2.70–7.80)	.003	3.10 (1.76–4.92)	.21	0.81 (0.68–0.89)	.13	0.75 (0.64–0.89)	.075
19F	2.85 (2.35–3.60)	.001	2.67 (2.16–4.18)	.076	0.75 (0.71–0.81	.004	0.81 (0.79–0.90)	.231
23F	3.53 (2.17–5.45)	<.0001	2.81 (2.14–4.36)	.012	1.15 (1.03–1.21	.23	1.17 (0.96–1.43)	.23

Data are presented as median (interquartile range [IQR]) unless otherwise indicated. Table shows the median fold-increase at 4 and 7 weeks postvaccination from baseline and IQR per serotype per vaccinated group (PCV13, n = 9 and HepA, n = 10). For comparison of immunoglobulin G levels between baseline and 4 or 7 weeks, adjusted P values are shown as calculated after correction for multiple comparisons using Dunn test.

Abbreviations: BL, baseline; HepA, hepatitis A vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.